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OBJECTIVES Our aim was to measure the cardiac phosphocreatine to adenosine triphosphate ratio
(PCr/ATP) noninvasively in patients and carriers of Xp21 muscular dystrophy and to
correlate the results with left ventricular (LV) function as measured by echocardiography.
BACKGROUND Duchenne and Becker muscular dystrophy (the Xp21 dystrophies) are associated with the
absence or altered expression of dystrophin in cardiac and skeletal muscles. They are
frequently complicated by cardiac hypertrophy and dilated cardiomyopathy. The main role of
dystrophin is believed to be structural, but it may also be involved in signaling processes.
Defects in energy metabolism have been found in skeletal muscle in patients with Xp21
muscular dystrophy. We therefore hypothesized that a defect in energy metabolism may be
part of the mechanism leading to the cardiomyopathy of Xp21 muscular dystrophy.
METHODS Thirteen men with Becker muscular dystrophy, 10 female carriers and 23 control subjects
were studied using phosphorus-31 magnetic resonance spectroscopy and echocardiography.
RESULTS The PCr/ATP was significantly reduced in patients (1.55 6 0.37) and carriers (1.37 6 0.25)
as compared with control subjects (2.44 6 0.33; p , 0.0001 for both groups). The PCr/ATP
did not correlate with LV ejection fraction or mass index.
CONCLUSIONS Altered expression of dystrophin leads to a reduction in the PCr/ATP. Since this reduction
did not correlate with indexes of left ventricular function, this raises the possibility of a direct
link between altered dystrophin expression and the development of cardiomyopathy in such
patients. (J Am Coll Cardiol 2000;36:1953–8) © 2000 by the American College of
Cardiology
Duchenne muscular dystrophy (DMD) and Becker muscu-
lar dystrophy (BMD) are inherited neuromuscular disorders
caused by an absence or decrease, respectively, in the
cytoskeletal protein called dystrophin. Dystrophin is a large
subsarcolemmal protein encoded by a gene at position 21 on
the long arm of the X chromosome (Xp21).
Patients with DMD have progressive skeletal muscle
weakness. Asymptomatic cardiac involvement is widespread
by the time patients reach their early teens, with 80% having
an abnormal electrocardiogram (ECG) echocardiogram, or
both (1). Skeletal muscle weakness remains the primary
limiting symptom, and this may explain why patients
remain asymptomatic from such cardiac involvement, even
late in the course of their disease. As the respiratory
component of patients’ symptoms is becoming more widely
treated (2), it is likely that recognition and management of
the cardiac component will assume greater importance.
In contrast, skeletal muscle weakness is milder in BMD.
Symptomatic cardiomyopathy may dominate the clinical
picture and is thought to be the leading cause of death in
such patients (3). Asymptomatic cardiac involvement in the
form of ECG and transthoracic echocardiographic (TTE)
abnormalities affects from 15% of patients ,16 years old to
70% of patients .40 years old (4).
Several studies have also demonstrated subclinical cardiac
involvement in female carriers of DMD. Although ECG or
TTE abnormalities are present in up to 40% of individuals
(5,6), clinical symptoms directly attributable to cardiomy-
opathy are comparatively rare, arising in ;5% of carriers (7).
Histologic evidence suggests that the characteristic skel-
etal muscle dystrophic changes of the Xp21 dystrophies are
also present in the heart (8), including patchy dystrophin
staining in heart biopsies of patients with BMD (9).
Phosphorus-31 magnetic resonance spectroscopy (31P-
MRS) is a noninvasive technique that allows the in vivo
detection of high energy phosphate–containing metabolites.
Cardiac 31P-MRS enables determination of the phospho-
creatine to adenosine triphosphate ratio (PCr/ATP), which
is an indicator of the energetic state of cardiac muscle (10).
The 31P-MRS studies in patients with DMD and BMD
and in female carriers have shown a reduced PCr/ATP in
skeletal muscle (11,12). In view of these findings and the
From the *Biochemical and Clinical Magnetic Resonance Unit, John Radcliffe
Hospital, Oxford, United Kingdom; †BHF Molecular Cardiology Group, Depart-
ment of Biochemistry, University of Oxford, South Parks Road, Oxford, United
Kingdom; ‡Department of Pediatrics and Neonatal Medicine, Imperial College of
Medicine, Hammersmith Campus, London, United Kingdom; and §Muscle and
Nerve Centre, Radcliffe Infirmary, Oxford, United Kingdom. The study was funded
by the British Heart Foundation and the Medical Research Council.
Manuscript received December 20, 1999; revised manuscript received May 30,
2000; accepted July 14, 2000.
Journal of the American College of Cardiology Vol. 36, No. 6, 2000
© 2000 by the American College of Cardiology ISSN 0735-1097/00/$20.00
Published by Elsevier Science Inc. PII S0735-1097(00)00960-8
similar histologic findings in heart and skeletal muscle, we
used 31P-MRS to investigate cardiac energetics in patients
with and carriers of Xp21 muscular dystrophy.
METHODS
Subjects. Potential participants in the study were identified
from a data base held by the Regional Genetics Service,
Churchill Hospital, Oxford, United Kingdom. Thirteen
men (mean age 30 years [range 12 to 48]) with BMD and
10 female carriers from families with DMD (mean age 46
years [range 26 to 62]) volunteered to take part in the study.
A diagnosis of BMD was made by the identification of a
mutation in the dystrophin gene (n 5 10) or by abnormal
dystrophin immunohistochemical staining on muscle biopsy
(n 5 3), or both. Carrier status was confirmed either by
DNA analysis (n 5 8) or by the presence of a family
pedigree, indicating that the participant may be an obligate
carrier (n 5 2). All subjects were examined and classified
into four functional groups: 1 5 raised serum creatine
kinase but otherwise asymptomatic; 2 5 symptomatic but
able to rise from a chair and climb stairs unaided; 3 5
ambulant but not able to climb stairs or rise from a chair
unaided; and 4 5 wheelchair-bound. Two patients and
eight carriers were in class 1; five patients and one carrier
were in class 2; three patients and one carrier were in class
3; and three patients were in class 4. Two carriers were thus
classified as manifesting carriers. Subjects had TTE and
31P-MRS of the heart performed. A similar number of age-
and gender-matched volunteers (12 men, mean age 32 years
[range 17 to 45]; 11 women; mean age 41 years [range 29 to
61]) were also studied by 31P-MRS only. These volunteers
were free of symptoms or signs of cardiovascular or neuro-
muscular disease and were not taking any cardioactive
treatments. All subjects gave written consent, and the study
was approved by the Central Oxford Research Ethics
Committee.
Cardiac 31P-MRS. SPECTRAL ACQUISITION. Patients
were studied using a 2-tesla whole-body magnet (Oxford
Magnet Technology, Oxford, United Kingdom), which was
interfaced to a Bruker Avance spectrometer (Bruker Med-
ical GmbH, Ettlingen, Germany). Patients were examined
at rest and lay prone on a custom-designed bed incorporat-
ing a gantry that allowed a range of surface coils to be
positioned beneath the precordium without moving the
subject. Patients were positioned with their heart at the
isocenter of the magnet, and this was confirmed using
standard multislice spin-echo proton images acquired using
a double-rectangular surface coil placed around the chest
(relaxation time [TR] 5 heart rate, echo time [TE] 5
25 ms, slice 5 10 mm, 5 slices, 15-mm spacing). These
images were also used to verify that the diaphragm would
not be within the field of view during the 31P acquisition.
The imaging coil was exchanged for a circular proton
surface coil (15-cm diameter) placed beneath the chest, and
shimming was performed to optimize the magnetic field
homogeneity over the heart. Finally, the coil was exchanged
for a 31P surface coil (8-cm diameter). To ensure full
localization of the 31P-MRS data to the heart, spectra were
acquired using a slice-selective, one-dimensional chemical
shift imaging (1D-CSI) sequence, including spatial presatu-
ration of lateral skeletal muscle, as follows. An oblique-
angled saturation slab was positioned from the proton
images across any skeletal muscle lateral to the surface coil,
and all 31P signals were saturated using two pairs of sinc
pulses at a 1:2 flip/angle ratio (13). An 8-cm thick transverse
slice was then excited, followed by one-dimensional phase
encoding into the chest to subdivide signals into 64 coronal
layers, each 1-cm thick (TR 5 heart rate, 16 averages). All
proton and 31P data at acquisition were cardiac gated using
a pulse oximeter probe placed on the subject’s finger.
SATURATION CORRECTION. The interpulse delay (TR) for
the 1D-CSI data set, which is determined by the heart rate,
is much shorter than the T1 relaxation times for ATP and
PCr. This leads to a reduction in measured signal intensity,
which is a function of the pulse angle, repetition rate and the
different T1 relaxation times of the metabolites. To allow
for this effect, saturation correction factors were measured
by obtaining 1D-CSI spectra from 31P phantoms of known
T1 relaxation times at different repetition rates. The ionic
strengths of the phantom were adjusted so that the pulse
angle at the surface of the coil was similar for equivalent
power levels for both phantoms and human subjects. The
T1 relaxation times of PCr and ATP were assumed to be
4.3 s and 2.5 s, respectively, these being the average of
published data (14).
As the magnitude of the correction factors is very sensi-
tive to the assumed T1 relaxation times, both the raw and
corrected ratios are presented in this report. It should be
noted, when comparing the corrected data from different
investigators, that there are several strategies for making this
saturation correction. The difference between the correction
factors for heart rates of 55 and 100 beats/min is only 4% to
5%. Thus, although the corrected PCr/ATP from different
reports may vary, the correction factor has little effect on the
relative differences between patients and control subjects, as
reported here.
Abbreviations and Acronyms
1D-CSI 5 one-dimensional chemical shift imaging
BMD 5 Becker muscular dystrophy
DMD 5 Duchenne muscular dystrophy
FID 5 free induction decay
LV 5 left ventricular
PCr/ATP 5 phosphocreatine to adenosine triphosphate
ratio
31P-MRS 5 phosphorus-31 magnetic resonance
spectroscopy
TE 5 echo time
TR 5 relaxation time
TTE 5 transthoracic echocardiogram
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DATA PROCESSING. The proton images were used to deter-
mine those spectra in the cardiac 1D-CSI data set that arose
from the myocardium. Spectral data were Fourier-
transformed, with 15 Hz of line broadening applied. The
cardiac rows with an acceptable signal to noise ratio were
extracted for analysis, and rows with a similar morphology
were added. The row immediately adjacent to the chest wall
was not analyzed to avoid contamination from residual
skeletal muscle signal. Spectra were fitted using a purpose-
designed interactive frequency domain-fitting program sim-
ilar to one recently described (15). Time-domain signals
were simulated for PCr, the three peaks of ATP, phos-
phodiesters and 2,3-diphosphoglycerate by incorporating
previous knowledge of peak chemical shifts and J couplings.
Each signal component was simulated allowing for missing
data points (due to the phase-encoding duration of the
acquisition experiment). Signal amplitude and exponential
decay of each component was adjustable, and gaussian decay
could be applied to the whole free induction decay (FID).
The simulated FID was Fourier-transformed. The root
mean square residual between the simulated and acquired
spectrum was calculated as a measure of the fit. After fitting,
the ATP signal was corrected for blood contamination
according to the amplitude of the 2,3-diphosphoglycerate
signal (16–18), and the PCr/ATP was calculated. The
calculated PCr/ATP was corrected for magnetic saturation
effects (as described earlier).
Echocardiography. Echocardiography was performed by
the same operator (J.G.C.) in all patients, using a SONOS
5500 (Hewlett-Packard, Bracknell, United Kingdom), and
images were stored on videotape or optical disk for later
analysis. Left ventricular dimensions were obtained using
M-mode echocardiography; ejection fraction was calculated,
when possible, from LV volumes (derived using the modi-
fied Simpson’s rule); and diastolic function was evaluated by
acquisition of a pulsed Doppler recording trace through the
mitral valve, with the sample volume positioned just above
the mitral valve tips. Left ventricular mass index was derived
from M-mode echocardiographic measurements using the
Wikstrand formula (19), which uses a modification of the
prolate ellipsoid geometric assumption of LV morphology,
and was adjusted for height, as recommended by de Simone
et al. (20).
Statistical analysis. The PCr/ATP data, comparing the
patient and carriers with their respective control subjects,
were analyzed using the Mann-Whitney U test, and echo-
cardiographic data were analyzed using the Student t test.
Results are reported as the mean value 6 SD. Statistical
significance was taken as p , 0.05.
RESULTS
Echocardiography. The results of TTE in the patient and
carrier groups are summarized in Table 1. Mild TTE
Table 1. Echocardiographic Features of Patients and Carriers*
ESD (cm) EDD (cm) IVSd (cm) PWd (cm) LVMI (g/m2.7) EF
Patient
1 3.64 4.94 0.73 0.60 40.3 0.54
2 4.23 5.00 0.66 0.51 25.8 0.42
3 4.19 5.13 0.84 0.72 30.1 0.41
4 3.22 4.87 0.96 0.87 41.1 0.48
5 3.90 5.29 0.87 0.78 35.6 0.43
6 4.92 5.68 1.03 0.69 42.6 0.35
7 4.14 5.59 0.77 0.67 31.9 0.35
8 3.33 5.00 0.94 1.03 48.9 0.51
9 3.74 4.14 1.12 1.12 42.2 0.52
10 3.04 4.98 0.72 0.72 25.1 0.62
11 3.68 5.19 0.85 0.85 33.1 0.59
12 2.74 4.81 1.25 1.04 49.7 0.56
13 3.12 4.83 0.71 0.93 33.6 0.59
Mean 6 SD 3.7 6 0.6 5.0 6 0.4 0.88 6 0.17 0.81 6 0.18 37 6 7.9 0.49 6 0.09
Carriers
1 4.44 5.82 0.94 0.81 57.8 0.50
2 3.40 4.27 0.76 0.55 25.5 0.50
3 3.39 4.79 0.89 0.89 35.6 0.57
4 3.17 4.72 0.71 0.6 24.5 0.51
5 3.51 5.14 0.57 0.85 39.2 0.65
6 4.50 5.65 0.9 0.74 45.1 0.54
7 3.65 5.77 0.61 0.79 37.6 0.62
8 3.18 4.88 0.85 0.9 41.7 0.51
9 2.70 5.03 1.05 1.11 60.5 0.63
10 3.14 4.63 0.86 0.86 41.2 0.53
Mean 6 SD 3.5 6 0.6 5.0 6 0.5 0.81 6 0.15 0.81 6 0.16 41 6 12 0.56 6 0.06
*Carriers 9 and 10 were manifesting carriers.
EDD 5 end-diastolic diameter; EF 5 ejection fraction; ESD 5 end-systolic diameter; IVSd 5 interventricular septal
thickness in diastole; LVMI 5 left ventricular mass index (upper limit of normal 5 51 g/m2.7 for males and 48 g/m2.7 for
females); PWd 5 posterior wall thickness in diastole.
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abnormalities were common among both cohorts of patients
with BMD and DMD carriers. No patient or carrier had
clinical symptoms or signs of heart failure. An ejection
fraction ,50% was present in 46% of the patient cohort.
Only one patient with BMD, the youngest, had a com-
pletely normal echocardiogram. None of the carriers had an
ejection fraction ,50%. Two carriers (one manifesting) had
an increase in LV mass index, but neither had objective
evidence of associated diastolic dysfunction. The mean
ejection fraction was significantly lower in the patient cohort
than in the carrier cohort (49 6 9% vs. 56 6 6%, p , 0.05).
However, there were no other significant differences in the
other echocardiographic variables.
31P-MRS data. Examples of cardiac spectra acquired from
a patient with BMD, a healthy volunteer and a DMD
carrier are shown in Figure 1. The PCr/ATP (uncorrected
for saturation) was significantly lower in the patients with
BMD as compared with the male control subjects (1.15 6
0.27 vs. 1.92 6 0.22, p , 0.001). It was also significantly
lower in the DMD carriers as compared with the female
control subjects (1.14 6 0.20 vs. 1.89 6 0.28, p , 0.001).
This difference remained significant after correction for
saturation effects (1.55 6 0.37 vs. 2.49 6 0.31, p , 0.001,
and 1.37 6 0.25 vs. 2.38 6 0.36, p , 0.001, respectively
[Fig. 2]). There was no correlation between the PCr/ATP
and any echocardiographic indexes of LV function.
DISCUSSION
In this study, we have shown, using 31P-MRS, that cardiac
energy metabolism is abnormal in both patients with and
carriers of Xp21 muscular dystrophy. A significant reduction
in the PCr/ATP was found in both subject groups as
compared with control groups. The magnitude of this
reduction was similar for both the patient and carrier
cohorts. The ratios were also similar between the manifest-
ing and nonmanifesting carriers. The presence of a reduced
PCr/ATP in the absence of either LV systolic or diastolic
dysfunction or an increase in LV wall thickness implies that
cardiac metabolic dysfunction in Xp21 muscular dystrophy
precedes the deterioration of LV function, and is not a result
of it. Our results are in contrast to most previous studies of
cardiac energetics in heart failure and cardiac hypertrophy,
which have shown a distinct correlation between a reduction
in the PCr/ATP and indexes of LV function (16–18).
Phosphocreatine is an important metabolite in the bio-
chemical pathways that supply ATP for muscle contraction.
Phosphocreatine can rapidly phosphorylate adenosine
diphosphate (ADP) to ATP through the creatine kinase
reaction, which is believed to be at equilibrium. Thus, PCr
buffers the concentration of ATP during sudden demands in
energy requirements, regulates ADP (a controller of oxida-
tive metabolism) and may also have a role in transferring
high energy phosphates from the mitochondria to the
myofibrils (the creatine kinase shuttle) (21).
Several studies have shown alterations in cardiac energet-
ics in various forms of cardiomyopathy and heart failure.
Lamb et al. (22) have reported a reduction in the PCr/ATP
in patients with cardiac hypertrophy secondary to essential
hypertension, the magnitude of which correlated with in-
dexes of diastolic dysfunction. Studies of valvular heart
disease have also demonstrated reductions in the PCr/ATP,
which appeared to correlate with measures of systolic LV
dysfunction (16). These studies have indicated that changes
in cardiac high energy phosphate metabolism are associated
with increased mechanical loading of the heart.
The cause of the reduced PCr/ATP in these studies is
Figure 1. Examples of spectra from a patient with BMD, a female carrier
of muscular dystrophy (MD) and a healthy volunteer.
Figure 2. Results of saturation-corrected PCr/ATP for patients with
BMD and carriers of muscular dystrophy (MD) as compared with control
subjects. * and **p , 0.0001.
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unclear, but several mechanisms may be important. First,
isolated perfused hearts have a lower PCr/ATP when
glucose is the sole substrate (23). Although shifts toward
increased glucose utilization have been found in rat models
of cardiac hypertrophy (24), it would seem unlikely that the
human heart would alter its metabolism to a sufficient extent
to produce such a pronounced fall in PCr/ATP, as we found
in our study. Second, severely compromised oxygen delivery
to the heart leads to anaerobic ATP production, and
decreased PCr/ATP has been found in animal hearts
subjected to ischemia (25). Again, this situation is unlikely
to exist in the human heart, other than in myocardial
regions supplied by an occluded coronary artery, and would
not account for major reductions in PCr/ATP under states
of adequate oxygen delivery at rest. Third, an increase in
cardiac work load (through volume or pressure loading)
could decrease PCr/ATP. Evidence for this is conflicting,
with some studies showing preserved PCr/ATP with in-
creased cardiac work load (26), and others showing a small
fall (5% to 10%) in PCr/ATP with dobutamine–atropine
stress (27). It seems unlikely that a moderate increase in
work load (i.e., a level induced by normal daily activity)
would cause a sustained fall in PCr/ATP, because increased
mitochondrial ATP production and improved oxygen de-
livery would more than compensate, thus suggesting that
other mechanisms are responsible for the perturbations in
energetics in heart failure. However, intrinsic defects of
mitochondrial function due to mutations affecting respira-
tory chain enzymes could impair this response. We have
recently found a reduced PCr/ATP in the heart of patients
with the mitochondrial encephalopathy, lactic acidosis and
stroke-like episodes (MELAS) syndrome in the absence of
defects of LV systolic function (28).
In this study, we found no relationship between the
PCr/ATP and indexes of systolic or diastolic function. The
ratio was uniformly reduced to an equal extent among
those with both normal and abnormal LV function. This
raises two intriguing questions. First, what is the cause of
the low PCr/ATP in our patients and carriers? Second,
does the PCr/ATP have any relationship to the pathophys-
iologic mechanisms of cardiomyopathy in Xp21 muscular
dystrophy?
Cause of reduced PCr/ATP. Because there was no evi-
dence of increased afterload or reduced oxygen delivery in
our subject group, alternative mechanisms must be consid-
ered. Although there is some evidence (29) for a decrease in
respiratory chain complex activity in Xp21 muscular dystro-
phy (mdx mouse), other studies have suggested that mito-
chondrial function is not severely impaired (12), and thus it
seems unlikely that this would account for our results.
The most likely explanation for our findings is a reduction
in creatine. Two studies have shown a reduction in creatine
content in human cardiomyopathies (30,31), when mea-
sured in vitro from cardiac biopsy specimens, and there are
similar findings in animal models of myocardial infarction
(32) and heart failure (33). In vivo support for this data has
been described by Bottomley et al. (34), who found, using
proton MRS, a reduction in the creatine content in infarct-
related regions of human myocardium. A reduction in
creatine, through the creatine kinase reaction—creatine 1
ATP7 ADP 1 H1 1 PCr—leads to a fall in PCr, as long
as the ratio (ADP)(H1)/(ATP) remains constant. Recent
evidence in a dog pacing model of heart failure suggests that
there is a rise in this ratio due to a 20% reduction in ATP
in advanced heart failure (33). In the same study, a fall in
creatine of 41% was found, suggesting that a reduction in
PCr/ATP is predominantly due to loss of creatine.
Relationship to pathophysiology of cardiomyopathy in
Xp21 muscular dystrophy. The most important function
of dystrophin appears to be membrane stabilization, al-
though other properties such as linkage of force transduc-
tion between the intracellular and extracellular environ-
ments may contribute to the clinical phenotype of
dystrophin deficiency (35). Ortiz-Lopez et al. (36) postu-
lated that a failure to stabilize the membrane, particularly
during repeated contraction of the heart, could lead to
long-term loss of muscle integrity and cardiomyopathy.
This reduction in membrane integrity may increase leakage
of intracellular metabolites essential for muscle contraction,
such as creatine. Thus, an energetic abnormality may be an
important contributing mechanism leading to progression
of cardiomyopathy in patients with DMD and BMD.
Dystrophin may also be involved in the regulation of ion
channels, such as the sodium-dependent membrane-bound
creatine transporter, and alteration in localization or func-
tion of this transporter may lead to decreased intracellular
creatine. Disruption of actin binding and interference with
calcium regulation (37) may increase ATP turnover and
exacerbate the deficiency of PCr. Studies in animal models
of muscular dystrophy may help unravel these additional
potential mechanisms.
Given that the spectra from the skeletal muscle, dia-
phragm and myocardium all contain peaks from PCr and
ATP, the potential for contamination of cardiac signal from
the surrounding tissue must be considered when interpret-
ing our results. We used image-guided placement of a
relatively small surface coil in conjunction with slice-
selective acquisition to minimize contributions from the
diaphragm. Slice selection is widely used in magnetic
resonance imaging and is known to have high selectivity
(.99%); thus, the potential for contamination from the
diaphragm is minimal. Phantom data (unpublished) show
that the phase-encoding scheme used to encode spectra with
depth into the chest shows no cross-contamination of
spectra from compartments that are separated by .5 mm.
In our analysis, there was always at least one row (10 mm)
between spectral rows containing skeletal muscle signal
from the anterior chest wall and the row(s) assigned to
myocardium. Thus, contamination from the chest wall, we
believe, was also minimal.
Furthermore, previous studies from our institution, which
has investigated phosphorus metabolites in the skeletal
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muscle of patients with BMD (11,12), have shown a
reduction in the PCr/ATP of 15% between patients and
control subjects. We also analyzed the PCr/ATP in the
skeletal muscle row of the cardiac data set in our patients,
carriers and control subjects, and we found a 17% reduction
in PCr/ATP between the patient and carrier groups and
control group. Our results suggest that it is unlikely that
skeletal muscle contamination of the cardiac signal could
account for the 38% to 42% reduction in cardiac PCr/ATP
that we found between our patients with BMD and DMD
carriers and control subjects.
There is much controversy as to whether abnormalities of
cardiac energetics are the cause or the consequence of
cardiac hypertrophy and heart failure. The consistent find-
ing in our study of reduced PCr/ATP, which did not
correlate with ejection fraction or LV mass index, adds
further weight to the hypothesis that an abnormality of
cardiac energetics is important in the etiology of cardiomy-
opathy in Xp21 muscular dystrophy. Furthermore, knowl-
edge of the mechanism by which a loss of dystrophin leads
to cardiomyopathy may increase our understanding of the
pathophysiologic mechanisms behind the development of
cardiac failure in other cardiomyopathies.
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